title: Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
abstract: OBJECTIVE
  To determine the maximum tolerated dose (MTD), recommended dose (RD), and activity of combined docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy on metastatic gastric cancer.
  
  
  METHODS
  Docetaxel and oxaliplatin were administered intravenously on day 1 and S-1 was administered orally on days 1-14 of every 21-day cycle. The doses of docetaxel/oxaliplatin/S-1 in the phase I study were level -1A, 52.5/80/60 mg/m(2); level -1B, 52.5/80/80 mg/m(2); level 1A, 52.5/105/80 mg/m(2); level 1B, 52.5/130/80 mg/m(2); level 2A, 60/105/80 mg/m(2); level 2B, 60/130/80 mg/m(2); level 3A, 67.5/105/80 mg/m(2); level 3B, 67.5/130/80 mg/m(2); level 4A, 75/105/80 mg/m(2); level 4B, 75/130/80 mg/m(2).
  
  
  RESULTS
  Nine patients were enrolled. One of six patients at level 1A and two of three patients at level 1B developed dose-limiting toxicity (febrile neutropenia) during the initial two cycles. Therefore, the doses used at levels 1B and 1A were defined as the MTD and RD, respectively. All patients were evaluated for toxicity and response. Six partial responses were noted, and the overall response rate was 67%.
  
  
  CONCLUSIONS
  The RD of the DOS regimen in patients with advanced gastric cancer was docetaxel 52.5 mg/m(2) and oxaliplatin 105 mg/m(2) on day 1 and S-1 80 mg/m(2) on days 1-14 of every 21-day cycle. A phase II study using the RD is currently underway.
authors.affiliation: Department of Internal Medicine, Hallym University Medical Center and Hallym University College of Medicine, Anyang, South Korea. fhdzang@hallym.or.kr
authors.forename: Dae Young
authors.initials: DY
authors.lastname: Zang
authors.forename: Dae Hyun
authors.initials: DH
authors.lastname: Yang
authors.forename: Min-Jeong
authors.initials: MJ
authors.lastname: Kim
authors.forename: Kyung Mi
authors.initials: KM
authors.lastname: Jang
authors.forename: Se Won
authors.initials: SW
authors.lastname: Hwang
authors.forename: Kyo-Sang
authors.initials: KS
authors.lastname: Yoo
authors.forename: Taeho
authors.initials: T
authors.lastname: Han
authors.forename: Ho Young
authors.initials: HY
authors.lastname: Kim
authors.forename: Hyo Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Jung Hye
authors.initials: JH
authors.lastname: Kwon
authors.forename: Hun Ho
authors.initials: HH
authors.lastname: Song
authors.forename: Sarah
authors.initials: S
authors.lastname: Park
authors.forename: Joo Young
authors.initials: JY
authors.lastname: Jung
authors.forename: Hyeong Su
authors.initials: HS
authors.lastname: Kim
authors.forename: Jung Han
authors.initials: JH
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D009944:Organoplatinum Compounds; D043823:Taxoids; D000077150:Oxaliplatin; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid